ロード中...
Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation
BACKGROUND: Ivacaftor (VX-770) is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator that was approved in the United States for the treatment of cystic fibrosis (CF) in patients ≥ 6 years of age who have a G551D mutation; however, the most prevalent disease-causing CFTR mutatio...
保存先:
| 主要な著者: | , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American College of Chest Physicians
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3435140/ https://ncbi.nlm.nih.gov/pubmed/22383668 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1378/chest.11-2672 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|